MedTrace Logo

Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess

NCT01422707 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2018-07-19

No results posted yet for this study

Summary

Short term hydrocortisone to test whether improves excess androgen production from adrenal gland and ovaries

Conditions

  • Hyperandrogenemia
  • Obesity
  • Polycystic Ovary Syndrome

Interventions

DRUG

Hydrocortisone

10 mg/m2/per day PO at bedtime (X4 weeks)

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Christine M. Burt Solorzano, MD · University of Virginia

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
7 Years
Max Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-19
Primary Completion
2018-07-17
Completion
2018-07-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01422707 on ClinicalTrials.gov